Developing Trojan horses to Induce, Diagnose and Suppress Alzheimer’s Pathology

Monoclonal antibodies for receptors on blood-brain barrier can act as molecular Trojan horses to transport the fused novel classes of re-engineered AD causative agents, diagnostic probes, or multiple function neurovascular medicines across the BBB via receptor-mediated transport to cause, diagnose, or improve the AD phenotype, respectively.